Reports - Parkinson’s Disease Treatment Market
HealthcareParkinson’s Disease Treatment Market
Parkinson’s Disease Treatment Market Valuation and Growth Forecast 2025-2035 by Drug Class (Carbidopa-levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT inhibitors, Anticholinergics, Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Parkinson’s Disease Treatment Market - Segment Analysis
1. Overview
2. Global Parkinson’s Disease Treatment Market, 2021 - 2035 (USD Million)
3. Global Parkinson’s Disease Treatment Market - by Drug Class
3.1. By Carbidopa-levodopa
3.2. By Dopamine Agonists
3.3. By MAO-B Inhibitors
3.4. By COMT inhibitors
3.5. By Anticholinergics
3.6. By Others
4. Global Parkinson’s Disease Treatment Market - by Distribution Channel
4.1. By Hospital Pharmacy
4.2. By Retail Pharmacy
4.3. By Online Pharmacy
5. Global Parkinson’s Disease Treatment Market - by region
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Latin America
5.5. Middle East & Africa
6. Market comparative analysis
Chapter 4 North America Parkinson’s Disease Treatment Market - Segment Analysis
1. Overview
2. North America Parkinson’s Disease Treatment Market, 2021 - 2035 (USD Million)
3. North America Parkinson’s Disease Treatment Market - by Drug Class
3.1. By Carbidopa-levodopa
3.2. By Dopamine Agonists
3.3. By MAO-B Inhibitors
3.4. By COMT inhibitors
3.5. By Anticholinergics
3.6. By Others
4. North America Parkinson’s Disease Treatment Market - by Distribution Channel
4.1. By Hospital Pharmacy
4.2. By Retail Pharmacy
4.3. By Online Pharmacy
Chapter 5 Europe Parkinson’s Disease Treatment Market - Segment Analysis
1. Overview
2. Europe Parkinson’s Disease Treatment Market, 2021 - 2035 (USD Million)
3. Europe Parkinson’s Disease Treatment Market - by Drug Class
3.1. By Carbidopa-levodopa
3.2. By Dopamine Agonists
3.3. By MAO-B Inhibitors
3.4. By COMT inhibitors
3.5. By Anticholinergics
3.6. By Others
4. Europe Parkinson’s Disease Treatment Market - by Distribution Channel
4.1. By Hospital Pharmacy
4.2. By Retail Pharmacy
4.3. By Online Pharmacy
Chapter 6 Asia Pacific Parkinson’s Disease Treatment Market - Segment Analysis
1. Overview
2. Asia Pacific Parkinson’s Disease Treatment Market, 2021 - 2035 (USD Million)
3. Asia Pacific Parkinson’s Disease Treatment Market - by Drug Class
3.1. By Carbidopa-levodopa
3.2. By Dopamine Agonists
3.3. By MAO-B Inhibitors
3.4. By COMT inhibitors
3.5. By Anticholinergics
3.6. By Others
4. Asia Pacific Parkinson’s Disease Treatment Market - by Distribution Channel
4.1. By Hospital Pharmacy
4.2. By Retail Pharmacy
4.3. By Online Pharmacy
Chapter 7 Latin America Parkinson’s Disease Treatment Market - Segment Analysis
1. Overview
2. Latin America Parkinson’s Disease Treatment Market, 2021 - 2035 (USD Million)
3. Latin America Parkinson’s Disease Treatment Market - by Drug Class
3.1. By Carbidopa-levodopa
3.2. By Dopamine Agonists
3.3. By MAO-B Inhibitors
3.4. By COMT inhibitors
3.5. By Anticholinergics
3.6. By Others
4. Latin America Parkinson’s Disease Treatment Market - by Distribution Channel
4.1. By Hospital Pharmacy
4.2. By Retail Pharmacy
4.3. By Online Pharmacy
Chapter 8 Middle East & Africa Parkinson’s Disease Treatment Market - Segment Analysis
1. Overview
2. Middle East & Africa Parkinson’s Disease Treatment Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Parkinson’s Disease Treatment Market - by Drug Class
3.1. By Carbidopa-levodopa
3.2. By Dopamine Agonists
3.3. By MAO-B Inhibitors
3.4. By COMT inhibitors
3.5. By Anticholinergics
3.6. By Others
4. Middle East & Africa Parkinson’s Disease Treatment Market - by Distribution Channel
4.1. By Hospital Pharmacy
4.2. By Retail Pharmacy
4.3. By Online Pharmacy
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Cerevel Therapeutics
2. Novartis AG
3. Teva Pharmaceutical Industries Ltd.
4. Merck & Co. Inc.
5. GlaxoSmithKline plc. (GSK)
6. AbbVie Inc.
7. H. Lundbeck A/S
8. Amneal Pharmaceuticals LLC
9. Supernus Pharmaceuticals Inc.
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By